July 09, 2015
Below are current clinical trials.7 studies in Amyloidosis
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to evaluate the usefulness of collecting health related quality of life data on newly diagnosed AL amyloidosis patients.
This clinical trial is studying long-term follow-up in patients who are or have participated in Children's Oncology Group studies. Developing a way to track patients enrolled in Children's Oncology Group studies will help doctors gather long-term follow-up information and may help the study of cancer in the future.
The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.
The purpose of this long-term survey is to better understand and characterize the natural history of transthyretin-associated amyloidoses (including ATTR-polyneuropathy, ATTR-cardiomyopathy, and wild-type ATTR-CM) by studying a large and diverse patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.
This is a phase 3, randomized, controlled, open-label, multicenter study of the oral formulation of dexamethasone plus IXAZOMIB compared with treatment chosen by the investigator from a prespecified list of regimens available in clinical practice. Treatment options will include: dexamethasone alone, dexamethasone plus an alkylating agent (melphalan or cyclophosphamide), or dexamethasone plus an immunomodulatory drug (IMiD, thalidomide or lenalidomide) in patients with relapsed or refractory AL amyloidosis. Crossover to the investigational treatment arm is not permitted during participation in this study.
The purpose of this study is to create a data collection and bioregistry of blood samples from Mayo Clinic patients with amyloidosis, suspected amyloidosis, and family members of patients with amyloidosis. This information will be available for future research about this spectrum of diseases.
The purpose of this study is to perform a paired comparison of CD34+ cell and lymphocyte yield, as well as cross-cellular contamination, on the same patient/donor using the 85 ml/min high flow rates versus the standard speeds of 65 ml/min for pre WBC of > 35 x109/L or 90 ml/min for pre WBC of ≤ 35 x109/L. Quantities of CD34+cells, lymphocytes, white blood cells, red blood cells, and platelets in the products would be compared. In addition, collection efficiency of CD34+ cells and lymphocytes would be compared. The yields and collection efficiencies would be used to judge the effect of the high flow rates.
- Gorevic PD. An overview of amyloidsosis. http://www.uptodate.com/home. Accessed May 4, 2014.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2014. https://www.clinicalkey.com. Accessed May 4, 2014.
- AskMayoExpert. When should light chain amyloidosis be suspected? Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
- Rajkumar SV. Clinical presentation, laboratory manifestations and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis). http://www.uptodate.com/home. Accessed May 4, 2014.
- Gorevic PD. Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases. http://www.uptodate.com/home. Accessed May 4, 2014.
- Hoffman R, et al. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2013. http://www.clinicalkey.com. Accessed May 5, 2014.
- Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. American Journal of Hematology. 2013;88:417.
- Dispenzieri A, et al. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Reviews. 2012;26:137.
- Vrana JA, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. In press. Accessed May 5, 2014.
- Warsame R, et al. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology. In press. Accessed May 5, 2014.
- Dispenzieri A, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014;100:383.
- Cook AJ. Decision Support System. Mayo Clinic, Rochester, Minn. May 8, 2014.
- Gorevic PD. Genetic factors in the amyloid diseases. http://www.uptodate.com/home. Accessed June 11, 2014.